Table 1.
Experimental runs, independent variables, and measured responses of the central composite experimental design for sofosbuvir bilosomal formulae.
| Formula code | X1: SAA/Drug ratio | X2: STC/S60 ratio | Y1: VS (nm) | Y2: PDI | Y3: ZP (mV) | Y4: EE (%) | DL (%w/w) |
|---|---|---|---|---|---|---|---|
| B1 | 1 | 1 | 177.5 ± 3.7 | 0.45 ± 0.03 | −30.4 ± 2.5 | 79.3 ± 5.1 | 15.9 ± 1.1 |
| B2 | 1 | 5.5 | 191.0 ± 4.0 | 0.77 ± 0.03 | −39.2 ± 1.8 | 58.7 ± 3.4 | 11.7 ± 1.5 |
| B3 | 1 | 10 | 149.0 ± 2.8 | 0.27 ± 0.01 | −49.5 ± 3.3 | 85.8 ± 3.7 | 17.2 ± 1.9 |
| B4 | 3 | 1 | 200.2 ± 3.3 | 0.37 ± 0.02 | −30.6 ± 1.2 | 62.1 ± 4.8 | 8.9 ± 0.8 |
| B5 | 3 | 5.5 | 192.0 ± 5.1 | 0.66 ± 0.04 | −42.2 ± 1.9 | 81.8 ± 3.3 | 14.2 ± 1.4 |
| 189.3 ± 4.4 | 0.72 ± 0.04 | −40.1 ± 3.7 | 57.4 ± 2.0 | 8.2 ± 0.5 | |||
| 201.3 ± 1.6 | 0.64 ± 0.02 | −42.5 ± 0.7 | 63.5 ± 1.9 | 9.1 ± 1.0 | |||
| 225.2 ± 6.9 | 0.70 ± 0.01 | −41.5 ± 2.8 | 12.6 ± 0.5 | 1.4 ± 0.2 | |||
| 202.8 ± 3.6 | 0.67 ± 0.01 | −41.3 ± 3.9 | 59.6 ± 4.1 | 8.5 ± 0.3 | |||
| B6 | 3 | 10 | 182.3 ± 1.4 | 0.35 ± 0.02 | −48.2 ± 3.5 | 13.9 ± 1.1 | 2.0 ± 0.3 |
| B7 | 5 | 1 | 238.1 ± 1.1 | 0.61 ± 0.05 | −37.1 ± 1.0 | 9.5 ± 0.3 | 1.1 ± 0.2 |
| B8 | 5 | 5.5 | 226.3 ± 5.8 | 1.00 ± 0.03 | −39.4 ± 3.5 | 7.2 ± 0.1 | 0.8 ± 0.1 |
| B9 | 5 | 10 | 240.0 ± 2.7 | 0.63 ± 0.01 | −44.4 ± 4.2 | 14.2 ± 1.2 | 1.6 ± 0.1 |
*n = 3, All formulae contained 100 mg drug and 300 mg l-α-Phosphatidylcholine.